Skip to main content
Premium Trial:

Request an Annual Quote

In Just One Dose

MIT's Tech Review reports on Alnylam's RNAi-based drug that, with one dose, lowers cholesterol by up to 60 percent in rodents and monkeys. The drug targets PCSK9, an enzyme that had been shown to affect LDL levels and people's risk of heart disease. The RNAi drug was bundled into lipid-based nanoparticles to be transported to the liver once injected. This drug, says the article, could be used in conjunction with statins to get LDL levels even lower.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.